Healthcare / Medical DistributionJakarta
$1500.00
-45.00 (-2.91%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 22%
FCF escenarios
weak_data · normalized FCF $155.5B · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$19.04T
P/E
31.9x
↑EV/EBITDA
21.9x
↑ROE
23.2%
↑Gross Margin
16.7%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.9%
FCF CAGR
+38.0%
FCF margin
7.8%
FCF / Net income
1.39x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.78T · net income $600.32B · FCF $837.41B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $10779.19B | $10779.19B | $10057.94B | $8197.75B | $7290.12B |
| Net Income | $600.32B | $600.32B | $462.65B | $371.34B | $356.73B |
| EBITDA | $820.75B | $820.75B | $638.55B | $515.86B | $503.45B |
| EPS | — | — | 36.00 | 29.00 | 28.00 |
| Gross Margin | 16.7% | 16.7% | 15.3% | 16.0% | 18.4% |
| Operating Margin | 6.8% | 6.8% | 5.6% | 5.2% | 6.0% |
| Net Margin | 5.6% | 5.6% | 4.6% | 4.5% | 4.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Current Ratio | 1.83 | 1.83 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $837.41B | $837.41B | $-218.87B | $155.53B | $318.57B |
| Returns | |||||
| ROE | 23.2% | 23.2% | 17.0% | 15.5% | 14.7% |
| Valuation | |||||
| P/E | 31.95 | 31.95 | 18.06 | 16.90 | 20.00 |
| EV/EBITDA | 21.86 | 21.86 | 12.28 | 10.76 | 11.92 |
| P/B | 7.37 | 7.37 | 3.04 | 2.59 | 2.93 |
| Growth & Yield | |||||
| Revenue Growth | 7.2% | 7.2% | 22.7% | 12.5% | — |
| EPS Growth | — | — | 24.1% | 3.6% | — |
| Dividend Yield | 4.8% | 4.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+133.8%
Start / end P/E
n/dx → n/dx
EPS bridge
36.00 → n/d
Residual
+129.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.